The recall was triggered by the presence of nitrosamine above the proposed limit.
Aurobindo Pharma USA has recalled two lots of Quinapril and Hydrochlorothiazide Tablets because of the presence of nitrosamine above the proposed limit. Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. But nitrosamine is generally considered carcinogenic, especially if present in high concentrations over time.
To date, Aurobindo Pharma has not received any reports of adverse events related to this recall.
Quinapril and Hydrochlorothiazide Tablets are fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide. This product is indicated for the treatment of hypertension.
The product under recall is 20 mg / 12.5 mg and are pink colored, scored, round shaped, debossed with ‘D’ on scored side and ‘19’on other side. It is supplied in 90s HDPE bottle.
The NDC number 65862-162-90, and the lots affected are QE2021005-A and QE2021010-A, both with an expiration date of January 2023. The product was distributed in May 2021.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More